Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

More Than Just Weight Loss: The Role of Bariatric Surgery in Curing Type 2 Diabetes

January 28, 2009

Analysis of:Diabetes Study Favors Surgery to Treat Obese | www.nytimes.com

20 million people in the US have Type 2 Diabetes. The disease is a leading cause of blindness, renal failure and amputations and patients have a demonstrably shortened life span. It is a chronic condition that medical treatment has thus far only been able to control, not cure. Morbid obesity is a cause of Type 2 diabetes. Bariatric surgery for morbid obesity has resulted in cures for Type 2 Diabetes. Interestingly, the success of gastric bypass in curing Type 2 Diabetes is due more to postoperative metabolic changes than simple weight loss, and this suggests that bariatric surgery may become an even more common operation in the near future.

Predicting response to anti-EGFR cancer therapy

January 5, 2009

Analysis of:Merck KGaA: Overall Survival in First-Line NSCLC Reaches 15 Months | www.drugs.com

Cetiximab and other anti-EGFR antibodies are effective late-line therapies for colorectal cancer, squamous cell cancers of the head and neck, and non-small cell lung cancer. Response rates are low (10-20%), but these response rates have been shown to be durable and do result in improved survival, particularly when combined with chemotherapeutic agents. The challenge now is to identify those patients who will best respond to these therapies.

Page : 11 to 2 of 2

Request a News Analysis

Subscribe to Updates

By RSS